Kristoffer Unterbruner

Kristoffer Unterbruner is a molecular biologist and portfolio manager at Medical Strategy, a healthcare investment management firm. He is recognized for his expertise in oncology and has provided insights into BioNTech's innovative approaches to cancer treatment, particularly highlighting the potential of their bispecific antibody, BNT327, which aims to challenge existing therapies in the market.